MannKind announces FDA acknowledgement of NDA resubmission for Afrezza

MannKind announced that the FDA has acknowledged the resubmission of a New Drug Application for AFREZZA Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014.

Advertisement